Xoma reports Q2 EPS 84c vs. (59c) last year

Reports Q2 revenue $11.1M vs. $1.7M last year. “The second quarter was marked by pipeline progress, the realization of several cash milestones, the addition of three commercial or late-stage programs, and the acquisition of Kinnate Pharmaceuticals,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Most important, children suffering from relapsed or refractory low-grade glioma have a new option with the approval of Day One’s OJEMDA, which is now our fifth commercial royalty. And finally, with a robust cash position in hand, we look to further solidify our foundation for future growth via a disciplined approach to capital deployment.”